M
Matthew C. Lucas
Researcher at Hoffmann-La Roche
Publications - 62
Citations - 957
Matthew C. Lucas is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Syk & Isoxazole. The author has an hindex of 18, co-authored 61 publications receiving 867 citations. Previous affiliations of Matthew C. Lucas include Cubist Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Inhibiting Stearoyl-CoA Desaturase Ameliorates α-Synuclein Cytotoxicity
Benjamin Vincent,Daniel F. Tardiff,Jeff S. Piotrowski,Rebecca Aron,Matthew C. Lucas,Chee Yeun Chung,Helene Bacherman,Yiqun Chen,Michelle Pires,Radha Subramaniam,Dimple B. Doshi,Heather Sadlish,Waseem K. Raja,Eric Solis,Vikram Khurana,Bertrand Le Bourdonnec,Robert H. Scannevin,Kenneth J. Rhodes +17 more
TL;DR: It is suggested that inhibition of fatty acid desaturation has potential as a therapeutic approach for the treatment of Parkinson's disease and other synucleinopathies.
Journal ArticleDOI
Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.
Brian Safina,Stewart J. Baker,Matt Baumgardner,Paul M. Blaney,Bryan K. Chan,Yung-Hsiang Chen,Matthew W. Cartwright,Georgette Castanedo,Christine Chabot,Arnaud J. Cheguillaume,Paul Goldsmith,David Michael Goldstein,Bindu Goyal,Timothy Hancox,Raj K. Handa,Pravin Iyer,Jasmit Kaur,Rama K. Kondru,Jane R. Kenny,Krintel Sussie Lerche,Jun Li,John Lesnick,Matthew C. Lucas,Cristina Lewis,Sophie Mukadam,Jeremy Murray,Alan Nadin,Jim Nonomiya,Fernando Padilla,Wylie Solang Palmer,Jodie Pang,Neil Anthony Pegg,Steve Price,Karin Reif,Laurent Salphati,Pascal Savy,Eileen Mary Seward,Stephen J. Shuttleworth,Sukhjit Sohal,Zachary Kevin Sweeney,Suzanne Tay,Parcharee Tivitmahaisoon,Bohdan Waszkowycz,Binqing Wei,Qin Yue,Chenghong Zhang,Daniel P. Sutherlin +46 more
TL;DR: The discovery of novel, potent, and selective PI3Kδ inhibitors are reported and a structural hypothesis for isoform (α, β, γ) selectivity gained from interactions in the affinity pocket is described.
Journal ArticleDOI
Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders: Recent progress and therapeutic perspectives
TL;DR: Recent insights into the emerging role of the SYK-BTK axis in innate immune cell function as well as in the maintenance of survival and homing signals for tumor cell progression are discussed.
Journal ArticleDOI
Potent and Highly Selective Benzimidazole Inhibitors of PI3-Kinase Delta
Jeremy Murray,Zachary Kevin Sweeney,Bryan K. Chan,Mercedesz Balazs,Erin K. Bradley,Georgette Castanedo,Christine Chabot,David Chantry,Michael Flagella,David Michael Goldstein,Rama K. Kondru,John Lesnick,Jun Li,Matthew C. Lucas,Jim Nonomiya,Jodie Pang,Stephen Price,Laurent Salphati,Brian Safina,Pascal Savy,Eileen Mary Seward,Mark Ultsch,Daniel P. Sutherlin +22 more
TL;DR: A series of potent and selective benzimidazole-based inhibitors of PI3Kδ are identified using a structure-based design approach and the pharmacokinetic properties and the ability of compound 5 to inhibit the function of B-cells in vivo are described.
Journal ArticleDOI
Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts.
Yimin Qian,Matthew Michael Hamilton,Achyutharao Sidduri,Gabriel Stephen Deems,Yonglin Ren,Ruoqi Peng,Rama K. Kondru,Arjun Narayanan,Terry Truitt,Rachid Hamid,Yun Chen,Lin Zhang,Adrian J. Fretland,Ruben Alvarez Sanchez,Kung-Ching Chang,Matthew C. Lucas,Ryan Craig Schoenfeld,Dramane Ibrahim Laine,Maria E. Fuentes,Christopher S. Stevenson,David C. Budd +20 more
TL;DR: LPA1 as the major receptor subtype mediating LPA-induced proliferation and contraction of NHLF is suggested, and pyrazole- and triazole-derived carbamates are designed and synthesised as LPA1-selective and LPA 1/3 dual antagonists.